NASDAQ:PTIX

Protagenic Therapeutics . Common Stock Stock Insider Trading

Healthcare > Biotechnology

Buy PTIX

*Your capital is at risk

$0.500

+0 (+0%)

At Close: Jun 03, 2026

Protagenic Therapeutics . Common Stock Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 8.63M and sold 0 PTIX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	8.63M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 15, 2025 Buy	Preferred Stock Series C	Evans Barrett Ex CEO	CEO / President	0 Value: $0
May 15, 2025 Buy	Preferred Stock Series C-1	Evans Barrett Ex CEO	CEO / President	0 Value: $0
May 15, 2025 Buy	Common Stock	Evans Barrett Ex CEO	CEO / President	0 Value: $0
May 15, 2025 Buy	Preferred Stock Series D	Evans Barrett Ex CEO	CEO / President	0 Value: $0
May 15, 2025 Buy	Preferred Stock Series D	Evans Barrett Ex CEO	CEO / President	0 Value: $0
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Wright Timothy R Director	Director	21 250 Value: $37.0K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Wright Timothy R Director	Director	21 250 Value: $37.0K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Stein Robert Benjamin Director	Director	75 000 Value: $130.5K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Barrage Khalil Director	Director	22 500 Value: $39.2K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Buell Jennifer Director	Director	75 000 Value: $130.5K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Armen Garo H Executive Chairman	CEO / President	250 000 Value: $435.0K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Corvese Brian Director	Director	43 750 Value: $76.1K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	100 000 Value: $174.0K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	100 000 Value: $174.0K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Corvese Brian Director	Director	43 750 Value: $76.1K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Armen Garo H Executive Chairman	CEO / President	250 000 Value: $435.0K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Buell Jennifer Director	Director	75 000 Value: $130.5K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Barrage Khalil Director	Director	22 500 Value: $39.2K
Mar 25, 2024 Buy	PTIX Common stock Options A-Award	Stein Robert Benjamin Director	Director	75 000 Value: $130.5K
Oct 12, 2023 Buy	PTIX Common Stock P-Purchase	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	8 000 Value: $6K
Oct 12, 2023 Buy	PTIX Common Stock P-Purchase	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	8 000 Value: $6K
May 17, 2022 Buy	PTIX Common Stock P-Purchase	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	8 000 Value: $6K
May 17, 2022 Buy	PTIX Common Stock P-Purchase	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	23 000 Value: $16.3K
May 17, 2022 Buy	PTIX Common Stock P-Purchase	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	23 000 Value: $16.3K
May 17, 2022 Buy	PTIX Common Stock P-Purchase	Arrow Alexander K. Chief Financial Officer	C-Suite Officer	8 000 Value: $6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROTAGENIC THERAPEUTICS, INC. COMMON STOCK

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York....

Read Full Profile Here